OBJECTIVE: To evaluate neointimal proliferation following placement of a new drug-eluting stent (BUMA) by optical coherence tomography (OCT). METHODS:Twenty-two patients with coronary artery disease were randomized into BUMA group (n=15) and Endeavor group (n=7) and underwent OCT imaging after 9 months of stent implantation. RESULTS: The neointima hyperplasia (NIH) thickness in BUMA group were significantly smaller than that in endeavor group (0.220-/+0.140 mm vs 0.269-/+0.207 mm, P<0.001), and the uncovered Struts were significantly lower in BUMA group than in Endeavor group (5.65% vs 6.56%, P<0.0001). The luminal late loss in BUMA group was also significantly lower (34.87-/+11.50 vs 40.82-/+18.53, P=0.025). CONCLUSION:BUMA stent is safe and effective for treatment of coronary artery disease.
RCT Entities:
OBJECTIVE: To evaluate neointimal proliferation following placement of a new drug-eluting stent (BUMA) by optical coherence tomography (OCT). METHODS: Twenty-two patients with coronary artery disease were randomized into BUMA group (n=15) and Endeavor group (n=7) and underwent OCT imaging after 9 months of stent implantation. RESULTS: The neointima hyperplasia (NIH) thickness in BUMA group were significantly smaller than that in endeavor group (0.220-/+0.140 mm vs 0.269-/+0.207 mm, P<0.001), and the uncovered Struts were significantly lower in BUMA group than in Endeavor group (5.65% vs 6.56%, P<0.0001). The luminal late loss in BUMA group was also significantly lower (34.87-/+11.50 vs 40.82-/+18.53, P=0.025). CONCLUSION:BUMA stent is safe and effective for treatment of coronary artery disease.
Authors: Bo Li; Qin Hua Jin; Yun Dai Chen; Chang Qian Wang; Bei Shi; Xi Su; Guo Sheng Fu; Yan Qing Wu; Xu Chen Zhou; Zu Yi Yuan Journal: Trials Date: 2019-06-07 Impact factor: 2.279